19F-MRS studies of fluorinated drugs in humans (Q33852961)

29 July 2017

1 reference

title

19F-MRS studies of fluorinated drugs in humans (English)

1 reference

29 July 2017

Wolf W

1

1 reference

29 July 2017

Presant CA

series ordinal

2

1 reference

29 July 2017

Waluch V

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Advanced Drug Delivery Reviews

29 July 2017

1 reference

29 July 2017

41

1 reference

29 July 2017

1

1 reference

29 July 2017

55-74

1 reference

19F MRS studies of fluoropyrimidine chemotherapy. A review

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Studies of human tumors by MRS: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Non-invasive physiology: 19F NMR of perfluorocarbons

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Nuclear magnetic resonance spectroscopy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Metabolism and mechanism of action of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Incorporation of 5-fluorouracil into hepatoma and normal tissue RNA at protein depletion in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Intra-hepatic arterial drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

New drugs in the treatment of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Progress in treating esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Chemotherapy and combined-modality therapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Which 5-fluorouracil regimen?--the great debate.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Biochemical modulation of 5-fluorouracil by PALA: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Uracil-tegafur in gastric carcinoma: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

An improved synthesis of 18F-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Distribution of 18F-5-Fluorouracil in tumor-bearing mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Dosimetry and preliminary human studies of 18F-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Field focusing n.m.r. (FONAR) and the formation of chemical images in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

New approach to metabolism of 5?-deoxy-5-fluorouridine in humans with fluorine-19 NMR

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

5-fluorouracil metabolism monitored in vivo by 19F NMR.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Association of intratumoral pharmacokinetics of fluorouracil with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

5-Fluorouracil revisited: a new perspective for treatment planning

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Direct detection of intratumoral 5-fluorouracil trapping using metabolic 19F MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Proton-decoupled 19F spectroscopy of 5-FU catabolites in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without int

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Pharmacokinetics in organs and the intact body: model validation and reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

The mechanism of tumor localization of gallium-67 citrate: role of transferrin binding and effect of tumor pH

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

An assessment of31P MRS as a method of measuring pH in rat tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

19F-[1H] nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Calculation of sensitivity correction factors for surface coil MRS

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Physiological pharmacokinetics and cancer risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Pharmacokinetic concepts ? Drug binding, apparent volume of distribution and clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Active Transport of 5-Fluorouracil and Its Energy Coupling in Ehrlich Ascites Tumor Cells1

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Intestinal brush border transport mechanism of 5-fluorouracil in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

In vivo 19F-NMR study of isoflurane elimination from brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Determination of halothane distribution in the rat head using 19F NMR technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Characterization of the cerebral distribution of general anesthetics in vivo by two-dimensional 19F chemical shift imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Magnetic resonance spectroscopy in affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Characterization of human brain pharmacokinetics using a two-compartment model.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900056-3

7 January 2021

10.1016/S0169-409X(99)00056-3

Identifiers

DOI

1 reference

29 July 2017

1 reference